» Articles » PMID: 23402606

Vitamin D in Chronic Liver Disease

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2013 Feb 14
PMID 23402606
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Chronic liver disease (CLD) and several related extrahepatic manifestations such as hepatic osteodystrophy are associated with deficiency of vitamin D, which has therefore been suggested as therapeutic target. Vitamin D undergoes hepatic 25-hydroxylation, rendering the liver critical to the metabolic activation of this vitamin. Vitamin D deficiency is highly prevalent in CLD patients, and vitamin D levels are inversely related to the severity of CLD. Declining levels of carrier proteins such as albumin and vitamin D-binding protein might also be critical in CLD. Intervention studies report improvements of CLD following supplementation, and benefits to health outcomes in particular with respect to hepatitis C virus infection have recently been documented.

Content: We discuss vitamin D sources, functions and metabolism with a focus on the inherent complications of analytical measurements, such as the interference of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D C-3 epimers. Global discrepancies in the definition of optimal serum 25-hydroxyvitamin D levels are covered, and the prevalence of vitamin D deficiency in CLD is reviewed. We also address the functional mechanisms underlying this deficiency, and refer to associations between genetic variation in vitamin D metabolism and CLD. Lastly, we consider the health implications of a vitamin D deficiency in CLD and consider therapeutic options.

Summary: Herein, we focus on the epidemiological and functional relationships between vitamin D deficiency and CLD, followed by a discussion of the potential implications for therapeutic interventions.

Citing Articles

Effects of vitamin D supplementation on the glycaemic indices, lipid profile and liver function tests in patients with cirrhosis: a double-blind randomised controlled trial.

Derogar Kasmaei S, Parastouei K, Hosseini Ahangar B, Saberifiroozi M, Taghdir M BMJ Nutr Prev Health. 2025; 7(2):e000938.

PMID: 39882304 PMC: 11773653. DOI: 10.1136/bmjnph-2024-000938.


Pemigatinib suppresses liver fibrosis and subsequent osteodystrophy in mice.

Mihara T, Tsuru Y, Kurosawa T, Nonoshita Y, Yamakawa Y, Hori M Hepatol Commun. 2025; 9(1.

PMID: 39774090 PMC: 11717528. DOI: 10.1097/HC9.0000000000000610.


Streamlined Vitamin D Metabolite Fingerprinting Analysis Using Isotope-Coded Multiplexing MS with Cost-Effective One-Pot Double Derivatization.

Schorr P, Stokes C, Volmer D ACS Omega. 2025; 9(51):50660-50670.

PMID: 39741865 PMC: 11684529. DOI: 10.1021/acsomega.4c08675.


Association between serum vitamin D status and severity of liver cirrhosis: implications for therapeutic targeting in Nigerian patients.

Adiri W, Basil B, Onyia C, Asogwa P, Ugwuanyi O, Obienu O BMC Gastroenterol. 2024; 24(1):259.

PMID: 39135191 PMC: 11318153. DOI: 10.1186/s12876-024-03353-1.


Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse.

Elsabaawy M, Alhaddad O Prz Gastroenterol. 2024; 19(1):6-17.

PMID: 38571544 PMC: 10985753. DOI: 10.5114/pg.2024.136361.